Cutaneous Melanoma
-
- HIRATSUKA Junichi
- Departments of Radiation Oncology, Kawasaki Medical School
-
- KAMITANI Nobuhiko
- Departments of Radiation Oncology, Kawasaki Medical School
-
- SASAOKA Shunsuke
- Departments of Dermatology, Kawasaki Medical School
-
- KUWABARA Chiaki
- Departments of Dermatology, Kawasaki Medical School
Bibliographic Information
- Other Title
-
- BNCTの臨床:皮膚悪性黒色腫
- BNCT ノ リンショウ : ヒフ アクセイ コクショク シュ
Search this article
Abstract
The study of boron neutron capture therapy(BNCT) for malignant melanoma was initiated by Y. Mishima and his associates. Following basic research of 13 years, this team started the first clinical trial of cutaneous melanoma BNCT using 10B-para-boronophenylalanine(BPA) in 1985. Since then, 32 patients have been treated. We developed the following regimen for BNCT of malignant melanoma:1) 170 - 250 mg/kg of BPA-fructose complex is administered by drip infusion over 3-hours. 2) The minimum dose for melanoma control by single irradiation is assumed to be 25Gy-eq. 3) The maximum tolerable dose to the skin by single irradiation is assumed to be 18Gy-eq. 4) As the therapeutic dose, the maximum tolerable dose to the skin itself is chosen. We report the clinical results of two patients with cutaneous melanoma treated by BNCT. We believe that cutaneous melanoma are suitable for BNCT and that the excellent results will have a great impact on patients in QOL.
Journal
-
- RADIOISOTOPES
-
RADIOISOTOPES 64 (1), 115-121, 2015
Japan Radioisotope Association
- Tweet
Details 詳細情報について
-
- CRID
- 1390001204156403712
-
- NII Article ID
- 130004803061
- 40020326038
-
- NII Book ID
- AN00351589
-
- ISSN
- 18844111
- 00338303
-
- NDL BIB ID
- 026034890
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- Crossref
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed